AMOEBA (EPA:AMEBA) - AMOÉBA announces the availability of its 2018 Registration Document including the Annual Financial Report

Transparency directive : regulatory news

25/04/2019 17:45

PRESS RELEASE

AMOÉBA announces the availability of its 2018 Registration Document including
                          the Annual Financial Report

Lyon (France), April 25th, 2019 - AMOÉBA (FR0011051598 - AMEBA), producer of a
biological biocide capable of eliminating bacterial risk in water and human
wounds, and a biocontrol product for plant protection, announces that it has
filed its 2018 Registration Document with the French Financial Markets
Authority (Autorité des marches financiers-AMF) on April 25, 2019 under number
D.19-0383.

The document may be viewed or downloaded on the company's website
www.amoeba-biocide.com under section " Investors / Regulatories information and
financial documents ". Copies of the Registration Document are also available
at the company's headquarters: 38, avenue des frères Montgolfier, 69680
Chassieu, France.

The 2018 Registration Document includes:

- the Annual Financial Report comprising the consolidated financial
   statements, the parent company financial statements, the management report
   and the related statutory auditors' reports
- the Board of Directors' corporate governance report.

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.

(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
      MarketsandMarkets
(3) : BCC Research, "Markets for Advanced Wound Management Technologies,
      " Wellesley, MA, 2017
(4) : Biopesticides  Worldwide Market 2013, CPL, Wallingford, UK

Contacts :
Amoéba
Valérie FILIATRE
Chief Financial Officer
04 26 69 16 00
valerie.filiatre@amoeba-biocide.com

source : webdisclosure.com

AMOEBA's latest news

07/10/2024 17:45

AMOEBA (EPA:AMEBA) - AMOÉBA announces the availability of its 2018 Registration Document including the Annual Financial Report

Transparency directive : regulatory news

AMOEBA's latest news

Other stories